Source:Current Problems in Cancer
Author(s): Erman Öztürk, Leyla Pur Özyiğit, Ayşe Bilge Öztürk, Meltem Olga Akay, Mustafa Çetiner, Burhan Ferhanoğlu
Rituximab is a chimeric monoclonal antibody that targets CD20 positive B cells and has a positive effect on both overall and progression-free survival in B cell lymphoid malignancies. Combination rituximab with chemotherapy treatment provide survival improvement. Although rituximab is an important treatment option in hematological malignancies, the risk of allergic reactions is high. These reactions are usually IgE-mediated and can be varied in regards of severity from urticaria to anaphylaxis. It is an option to interrupt the treatment and ommit rituximab therapy who had allergic reactions. Drug desensitization is another option and successful results have been reported by applying desensitization to such reactions. Drug desensitization alters the immune response to induce a state of temporary clinical tolerance to the allergic drug by giving gradual increasing of doses of drug at fixed time intervals. Herein we present 3 cases successfully treated with rituximab desensitization. The cases were using rituximab with the diagnosis of Burkitt lymphoma, follicular lymphoma and marginal zone lymphoma, respectively. Two cases had grade 2, one case had grade 3 systemic allergic reaction with rituximab. There was no known allergy history in all three cases. All patients tolerated the desensitization protocol. The subsequent treatments of the patients were also given by desensitization protocol. A total of 12 desensitizations were administered to 3 cases. No severe or life-threating reactions were observed in subsequent applications. To date applying desensitization protocols ensure rituximab treatment safely. Rituximab desensitization can be performed at trained allergy centers and it may be an appropriate option for rituximab allergic patients.
http://ift.tt/2vOfDzG
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου